VMA does not affect anti-VEGF treatment for polypoidal choroidal vasculopathy

The presence of vitreomacular adhesion had an insignificant effect on visual outcomes after intravitreal anti-VEGF injections for the treatment of polypoidal choroidal vasculopathy, according to a study.The retrospective study included 104 eyes of 102 patients with polypoidal choroidal vasculopathy. Eyes were assigned to two groups; 23 eyes had vitreomacular adhesion (VMA) and 81 eyes did not have VMA.Investigators compared logMAR best corrected visual acuity and central macular thickness between the groups at baseline and at 1, 3, 6 and 12 months after anti-VEGF treatment.

Full Story →